Method to elicit an antitumor response with human prostate-specific antigen
US5925362A · kind A · utility
29Cited by
8References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 1994 |
| Grant date | Jul 20, 1999 |
| Priority date | — |
| Expiry date | Aug 10, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/812
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of human PSA and expression system capable of generating in situ human PSA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.